Amogammadex
Amogammadex (Adamgammadex; Aom0498) is a modified γ-cyclodextrin (HY-W040040) derivative and neuromuscular blocking agent. Amogammadex forms inactive, tight inclusion complexes with free Rocuronium (HY-17033) and Vecuronium (HY-B0118A), and reverses the neuromuscular blockade induced by them in a concentration-dependent manner. Amogammadex can be used in research related to neuromuscular blockade reversal.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 1309580-40-2
- 화학식: C88H136N8O56S8
- 분자량:2458.56
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1309580-40-2
-
분자량 2458.56
-
화학식 C88H136N8O56S8
-
SMILES
CC(N[C@@](C(O)=O)([H])CSC[C@@H]1[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O[C@@H](O3)[C@H](O)[C@@H](O)[C@H](O[C@@H](O4)[C@H](O)[C@@H](O)[C@H](O[C@@H](O5)[C@H](O)[C@@H](O)[C@H](O[C@@H](O6)[C@H](O)[C@@H](O)[C@H]7[C@H]6CSC[C@@](C(O)=O)(NC(C)=O)[H])[C@H]5CSC[C@@](C(O)=O)(NC(C)=O)[H])[C@H]4CSC[C@]([H])(NC(C)=O)C(O)=O)[C@H]3CSC[C@@](NC(C)=O)([H])C(O)=O)[C@H](O2)CSC[C@](C(O)=O)([H])NC(C)=O)[C@H](O)[C@@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O)[C@@H](O7)O[C@@H]9CSC[C@](NC(C)=O)(C(O)=O)[H])O[C@@H]8CSC[C@@]([H])(C(O)=O)NC(C)=O)O1)=O
-
Synonyms
Adamgammadex; Aom0498
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
[1]. Qi, et al. 6-deoxy-6-thioether-amino acid cyclodextrin derivatives and preparation method thereof. WO2012068981A1. [Content Brief]
[2].
Zhao Y, et al. Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular block: a multicentre, randomised, double-blind, positive-controlled phase III trial. Br J Anaesth. 2025 Aug;135(2):331-339.
[Content Brief]
[3]. Stäuble CG, Blobner M. The future of neuromuscular blocking agents. Curr Opin Anaesthesiol. 2020 Aug;33(4):490-498. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Amogammadex Related Classifications
HY-159818 Related Classifications
Powered by Bioz